Form 4: NewAmsterdam Pharma Director James N. Topper Acquires Shares

Director James N. Topper reports the acquisition of NewAmsterdam Pharma Co N.V. shares through a transaction on March 4, 2025.

Summary

• On March 4, 2025, James N. Topper, a director of NewAmsterdam Pharma Co N.V., acquired 4,005 ordinary shares at a weighted average price of $21.0245.
• The shares were purchased in multiple transactions with prices ranging from $20.545 to $21.00.
• Following the transaction, Topper indirectly owns 3,012,434 shares through Frazier Life Sciences X, L.P. and 3,801,000 shares through Frazier Lifesciences Sponsor LLC.
• Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of share acquisition by a company director. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders and their confidence in the company's prospects.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence as it indicates a director's investment in the company.

Key Dates